ACTIVE

A.forall Group

Export PDF

Financial year 2024 · Closed on 31/12/2024

Net result-16,1 M €-137,0 %over 1 year

Revenue6,9 M €+23,5 %over 1 year

Equity127 M €-11,3 %over 1 year

Workforce6,6 ETP-2,9 %over 1 year

Identity

Source · BCE/KBO

A.forall Group is a Public limited company incorporated in 2017. Its main activity is: Activities of holding companies. Its registered office is in Anderlecht. It employs on average 6,6 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0684.777.042
Incorporation: 17/11/2017
Legal form: Public limited company
Registered office: Square Marie Curie 50
1070 Anderlecht · BruxellesSee on map
Contributed capital: 112 948 581,00 €
Latest accounts: 31/12/2024
Average workforce: 6,6 ETP

Activities (NACE)

64200Activities of holding companies· main 64210Activities of holding companies 82990Other business support service activities n.e.c.82990Other business support service activities n.e.c.64200Activities of holding companies 64210Activities of holding companies

Joint committees (1)

Signals

Solid equityHealthy social debtsHigh revenue

Financials

Source · NBB, 16 filings

Trend over 7 financial years

	2024		2023		2022		2021		2020
Income statement
Revenue	6,9 M €	+23.5%	5,6 M €	-17.8%	6,8 M €	-2.4%	7 M €	+26.3%	5,5 M €
EBITDA	-1,8 M €	-144%	-750,1 k €	-364%	284,3 k €	+200%	-283,5 k €	+42.8%	-495,9 k €
Operating result	-2 M €	-117%	-935 k €	-761%	141,4 k €	+137%	-380,7 k €	+30.3%	-546,3 k €
Net result	-16,1 M €	-137%	43,5 M €	+2270%	-2 M €	-115%	13,2 M €	+168%	-19,4 M €
Balance sheet
Equity	127 M €	-11.3%	143,1 M €	+43.7%	99,5 M €	-2.0%	101,6 M €	+14.9%	88,4 M €
Total assets	156,6 M €	-26.9%	214,2 M €	+30.1%	164,6 M €	-0.3%	165 M €	-24.6%	218,9 M €
Cash	80 k €	-90.9%	878,6 k €	+397%	176,8 k €	-22.7%	228,6 k €	-72.3%	823,9 k €
Debts	29,3 M €	-58.7%	70,8 M €	+9.2%	64,8 M €	+2.3%	63,3 M €	-51.3%	130,1 M €
Other
Workforce	6,6 ETP	-2.9%	6,8 ETP	0.0%	6,8 ETP	+6.2%	6,4 ETP	-29.7%	9,1 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 100 M€ and 250 M€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2024

6 active · 5 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Pharma Handshake1028.856.036Represented by Steen Vangsgaard	Director03/09/2025 → 28/06/2028
Damien Gaudin	Director17/11/2017 → 28/06/2028
Karsten Langer	Director17/11/2017 → 28/06/2028
Themtis0536.341.110Represented by Filip Van de Vliet	Managing director23/06/2018 → 28/06/2028Director20/06/2018 → 2023 accountsended
VS Pharma Consulting LLCRepresented by Jatin Shah	Director19/06/2019 → 28/06/2028
George Frederick Wilkinson	Director01/08/2018 → 28/06/2028

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Frederick Wilkinson	Director01/10/2018 → 2023 accounts
GRNR Invest0817.694.459Represented by Thomas Jacobsen	Director04/02/2020 → 23/06/2021
Hansfree BVRepresented by Hans Stols	Director19/06/2019 → 04/02/2020

Other companies at this address

Square Marie Curie 50 1070 Anderlecht

Company	CBE no.
A.forall Development● Active	0827.869.165
Maatschap Eden● Active	0730.754.250
MEDIGROUP● Active	0826.773.857
NEOGEN● Active	0445.922.856
S.A. ISTA N.V.● Active	0417.918.263

Full financial information

Source · NBB

	2024	2023	2022	2021	2020	2019
Type of account	Full model	Full model	Full model	Full model	Full model	Full model
Start of the financial year	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020	01/01/2019
Closing of the financial year	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020	31/12/2019
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	24/11/2025	14/11/2024	10/10/2023	05/12/2022	16/09/2021	15/07/2020
General meeting	14/11/2025	12/11/2024	05/10/2023	02/12/2022	15/09/2021	08/07/2020
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 16 filings

Model	Closing	General meeting	Filed	Language	Document
Full model	31/12/2024	14/11/2025	24/11/2025	Dutch	PDF
Consolidated accounts	31/12/2024	14/11/2025	24/11/2025	Dutch	PDF
Full model	31/12/2023	12/11/2024	14/11/2024	Dutch	PDF
Consolidated accounts	31/12/2023	12/11/2024	14/11/2024	Dutch	PDF
Full model	31/12/2022	05/10/2023	10/10/2023	Dutch	PDF
Consolidated accounts	31/12/2022	05/10/2023	10/10/2023	Dutch	PDF
Full model	31/12/2021	02/12/2022	05/12/2022	Dutch	PDF
Consolidated accounts	31/12/2021	02/12/2022	09/12/2022	Dutch	PDF
Full model	31/12/2020	15/09/2021	16/09/2021	Dutch	PDF
Consolidated accounts	31/12/2020	15/09/2021	16/09/2021	Dutch	PDF
Full model	31/12/2019	08/07/2020	15/07/2020	Dutch	PDF
Consolidated accounts	31/12/2019	08/07/2020	14/07/2020	Dutch	PDF
Full model	31/12/2018	28/06/2019	10/07/2019	Dutch	PDF
Consolidated accounts	31/12/2018	31/12/2018	23/07/2019	Dutch	PDF
Full model	31/03/2018	11/10/2018	23/10/2018	Dutch	PDF
Consolidated accounts	31/03/2018	11/10/2018	24/10/2018	Dutch	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 100 M€ and 250 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2024

6 active · 5 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Pharma Handshake1028.856.036Represented by Steen Vangsgaard	Director03/09/2025 → 28/06/2028
Damien Gaudin	Director17/11/2017 → 28/06/2028
Karsten Langer	Director17/11/2017 → 28/06/2028
Themtis0536.341.110Represented by Filip Van de Vliet	Managing director23/06/2018 → 28/06/2028Director20/06/2018 → 2023 accountsended
VS Pharma Consulting LLCRepresented by Jatin Shah	Director19/06/2019 → 28/06/2028
George Frederick Wilkinson	Director01/08/2018 → 28/06/2028

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
Frederick Wilkinson	Director01/10/2018 → 2023 accounts
GRNR Invest0817.694.459Represented by Thomas Jacobsen	Director04/02/2020 → 23/06/2021
Hansfree BVRepresented by Hans Stols	Director19/06/2019 → 04/02/2020

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette

Mandates24/11/2025
ONTSLAGEN - BENOEMINGEN
PDF
Mandates06/05/2024
ONTSLAGEN - BENOEMINGEN
PDF
Other11/01/2024
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - BENAMING
PDF
Mandates23/12/2022
ONTSLAGEN - BENOEMINGEN
PDF
Other29/09/2022
DIVERSEN
PDF
Other22/10/2021
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
PDF
Mandates26/07/2021
KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
PDF
Mandates13/07/2021
ONTSLAGEN - BENOEMINGEN
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts

Year

Identity

Incorporation

Name

Registered office

Annual accounts

Filings7 filings

Mandates

Pharma Handshake

VS Pharma Consulting LLC

Themtis

George Frederick Wilkinson

Damien Gaudin

Karsten Langer

Frederick Wilkinson

GRNR Invest

Hansfree BV

SVR Management

Fabio Pesiri

201720182019202020212022202320242025202620272028

A.forall GroupAlter Pharma Group

Square Marie Curie 50, 1070 Anderlecht

Director

Managing directorDirector

Director

CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE

Registered address	Period	Source
Square Marie Curie 50, 1070 AnderlechtCurrent	accounts 2021 → 2024	Accounts 2024 · 2025-00570555

Company names

Source · NBB annual accounts, CBE

Name	Period	Source
A.forall GroupCurrent	accounts 2023 → 2024	Accounts 2024 · 2025-00570555
Alter Pharma Group	accounts 2021 → 2022	Accounts 2022 · 2023-00480801

Events

10/10/2025
nominationPharma Handshake BV · bestuurder
03/09/2025
nominationSteen Vangsgaard · bestuurder
2024
Annual accounts 2024-16,1 M €↓
2023
Annual accounts 202343,5 M €↑
2023
Name changeA.forall Group
05/10/2023
reconductionDeloitte Bedrijfsrevisoren BV · commissaris
2022
Annual accounts 2022-2 M €↓
02/12/2022
reconductionKarsten Langer · bestuurder
02/12/2022
reconductionDamien Gaudin · bestuurder
02/12/2022
reconductionFilip Van de Vliet · bestuurder (vertegenwoordiger van Themtis BV)
02/12/2022
reconductionJatin Shah · bestuurder (vertegenwoordiger van VS Pharma Consulting LLC)
02/12/2022
reconductionGeorge Frederick Wilkinson · bestuurder
2021
Annual accounts 202113,2 M €↑
2020
Annual accounts 2020-19,4 M €↓
2018
Annual accounts 2018-1,7 M €↓
2018
Annual accounts 2018-562,2 k €
17/11/2017
IncorporationPublic limited company

A.forall Group

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline

Registered offices

Company names

Events